Pipeline

Product
Candidate

R&D

Manufacturing

FDA
Master File

Integration into partner vaccine

Product Candidate

Cell culture QS-21

R&D

GMP Manufacturing

FDA Master File

Integration into Partner Vaccine

QS-21 is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet.

QS-21’s advantages relative to traditional vaccine adjuvants include:
  • An increase in the titer of antibody response
  • Stimulation of T Cell immune response
  • A reduction of the antigen dose requirement to achieve optimal immune response
  • Generation of immune responses to viral, bacterial and parasitic pathogens
More Info
QS-21 is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet.

QS-21’s advantages relative to traditional vaccine adjuvants include:
  • An increase in the titer of antibody response
  • Stimulation of T Cell immune response
  • A reduction of the antigen dose requirement to achieve optimal immune response
  • Generation of immune responses to viral, bacterial and parasitic pathogens

Product Candidate

Cell culture QS-7

R&D

GMP Manufacturing

FDA Master File

Integration into Partner Vaccine

QS-21 STIMULON is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 STIMULON is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet. QS-21’s advantages relative to traditional vaccine adjuvants include: • An increase in the titer of antibody response • Stimulation of T Cell immune response • A reduction of the antigen dose requirement to achieve optimal immune response • Generation of immune responses to viral, bacterial and parasitic pathogens
More Info
QS-21 STIMULON is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 STIMULON is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet. QS-21’s advantages relative to traditional vaccine adjuvants include: • An increase in the titer of antibody response • Stimulation of T Cell immune response • A reduction of the antigen dose requirement to achieve optimal immune response • Generation of immune responses to viral, bacterial and parasitic pathogens

Product Candidate

Cell culture QS-X

R&D

GMP Manufacturing

FDA Master File

Integration into Partner Vaccine

QS-21 STIMULON is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 STIMULON is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet. QS-21’s advantages relative to traditional vaccine adjuvants include: • An increase in the titer of antibody response • Stimulation of T Cell immune response • A reduction of the antigen dose requirement to achieve optimal immune response • Generation of immune responses to viral, bacterial and parasitic pathogens
More Info
QS-21 STIMULON is a potent adjuvant whose mechanisms of action address a common problem of developing vaccines: the poor immunogenicity of many antigens. QS-21 STIMULON is is a key component of multiple approved vaccines, including Shingrix and Mosquirix. It has has also been featured in more than 350 peer-reviewed scientific and clinical articles such as Science, Nature, The New England Journal of Medicine and The Lancet. QS-21’s advantages relative to traditional vaccine adjuvants include: • An increase in the titer of antibody response • Stimulation of T Cell immune response • A reduction of the antigen dose requirement to achieve optimal immune response • Generation of immune responses to viral, bacterial and parasitic pathogens

Some kind of intro title here?

Maybe an image or diagram here? if not, I’ll just make the text full width.

Adjuvants are immunological helpers that make vaccines more effective, longer lasting, and more accessible. While many vaccines consist simply of a formulated antigen capable of providing protection from a disease, some antigens are unable to meet the criteria required to become a successful vaccine. There are many reasons an antigen could fail on its own. For example, an antigen may not be immunogenic enough to trigger the desired protection, or it may only provide effective protection for a few months. Some vaccines, while they have effective antigens, may be too expensive to manufacture at scale and are inaccessible to low-income patients. Some may cause significant side effects. Adding an adjuvant can offer a solution to these problems.

The primary role of an adjuvant in a vaccine is to improve the body’s immune response to the vaccine. By stimulating a more powerful response than an antigen may be able to achieve on its own, the adjuvant can make the vaccine more effective in several ways. Adjuvants can in some cases also extend the long-term durability of the vaccine, removing the need for boosters and protecting the patient for years after dosing. Beyond triggering an optimal immune response, adjuvants can also be used to decrease the amount of antigen required in a vaccine, allowing for dose sparing, which can reduce side effects and make vaccines more affordable to populations worldwide.

Adjuvants have been used in vaccines for decades, but vaccine developers have traditionally focused on antigen development rather than optimizing adjuvants. Currently, there are only five adjuvants used in approved products, with the fifty-year-old adjuvant alum being used in the vast majority of adjuvanted vaccines. While these adjuvants have been effective in supporting existing vaccines, there remains the opportunity to fuel new vaccines and even save previously failed vaccines by using adjuvants optimized for the modern day.

SaponiQx is revolutionizing the vaccine landscape by innovating from the adjuvant side of vaccine development. By ensuring a secure supply of the premiere adjuvant QS-21 STIMULON™ and spearheading the development of a pipeline of novel adjuvants, SaponiQx will make vaccines more effective and more accessible to patients worldwide.

SaponiQx
3 Forbes Road
Lexington, MA 02421-7305
T: 781.674.4445

Linkedin Twitter